IDYA

#1533
IDEAYA Biosciences, Inc. - Common Stock
40.1 1 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
40.11
40.11
Jahresspanne
26.81
42.68
Tagesänderung
-3.97%
Monatliche Änderung
+13.08%
6 month change
+26.09%
Jahresänderung
+23.11%
Vorheriger Schlusskurs
41.7 7
Open
40.1 1
Tief
40.1 1
Hoch
40.1 1
Volumen
159
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
IDEAYA Biosciences, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
IDEAYA Biosciences, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K

IDEAYA Biosciences, Inc. current report, Q2 FY2025

Full document

Business Context and Reporting Period

This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by IDEAYA Biosciences, Inc. on June 24, 2025. The filing details the voting results for three proposals presented to stockholders of record as of April 28, 2025, when 87,577,550 shares were outstanding.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

The filing discloses the outcomes of three stockholder proposals:

  • Proposal 1 (Election of Directors):
    • Jeffrey L. Stein, Ph.D. was elected with 69,077,770 votes for, 7,955,948 votes withheld, and 3,030,741 broker non-votes.
    • Scott W. Morrison was elected with 42,132,938 votes for, 34,900,780 votes withheld, and 3,030,741 broker non-votes.
  • Proposal 2 (Ratification of Auditors): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025. The vote was 79,645,454 for, 228,609 against, and 190,397 abstentions.
  • Proposal 3 (Executive Compensation): The non-binding advisory vote to approve named executive officer compensation passed with 59,798,805 votes for, 17,040,207 votes against, 194,706 abstentions, and 3,030,741 broker non-votes.

Guidance, Outlook, and Risks

This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the tabulation of votes from the Annual Meeting.

Key Facts for Investor Verification

  • Verify the official proxy statement (Schedule 14A) filed on April 30, 2025, for detailed biographies of the elected directors and the rationale behind the executive compensation plan.
  • Note the significant number of votes withheld for Scott W. Morrison (34.9 million) compared to Jeffrey L. Stein (7.9 million), indicating potential stockholder sentiment differences regarding specific director nominees.
  • Confirm the total outstanding share count of 87,577,550 as of the record date to assess voting participation rates.
  • Review subsequent filings for the company's financial performance, as this 8-K contains no financial data.

Nachrichten